Holen Sie sich die Stockscreener-App
1.03
1.98%
0.02
Vorhandelsmarkt:
1.06
0.03
+2.91%
Schlusskurs vom Vortag:
$1.01
Offen:
$1.02
24-Stunden-Volumen:
2.48M
Relative Volume:
0.45
Marktkapitalisierung:
$300.79M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-63.08M
KGV:
-3.8148
EPS:
-0.27
Netto-Cashflow:
$-72.53M
1W Leistung:
-3.74%
1M Leistung:
-2.83%
6M Leistung:
+36.19%
1J Leistung:
-37.20%
1-Tages-Spanne:
$0.99
$1.05
1-Wochen-Bereich:
$0.97
$1.09
52-Wochen-Spanne:
$0.515
$1.72
Ocugen Inc Stock (OCGN) Company Profile
Firmenname
Ocugen Inc
Sektor
Branche
Telefon
484-328-4701
Adresse
11 GREAT VALLEY PARKWAY, MALVERN, PA
Vergleichen Sie OCGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.03 | 312.47M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-15 | Eingeleitet | Maxim Group | Buy |
| 2023-03-01 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | Eingeleitet | Mizuho | Buy |
| 2022-06-15 | Fortgesetzt | ROTH Capital | Buy |
| 2022-06-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-07-26 | Eingeleitet | Noble Capital Markets | Outperform |
| 2021-06-11 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2021-05-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
Alle ansehen
Ocugen Inc Aktie (OCGN) Neueste Nachrichten
Ocugen Strengthens Leadership and Advisory Board as It Targets Three Biologics Filings in Three Years - MyChesCo
Ocugen, Inc. Announces New Appointments to its Retina Scientific Advisory Board and Executive Leadership Team - VisionMonday.com
What analysts say about Ocugen Inc. stockHigh-velocity capital appreciation - jammulinksnews.com
Is Ocugen Inc. a good long term investmentExtraordinary performance - Autocar Professional
What drives Ocugen Inc. stock priceDynamic profit opportunities - jammulinksnews.com
Ocugen announces appointments to retina scientific advisory board & executive leadership team - Ophthalmology Times
Ocugen, Inc. Announces New Appointments to Retina Scientific Adv - GuruFocus
Ocugen expands advisory board and leadership team for gene therapy push - Investing.com Australia
Ocugen, Inc. Strengthens Retina Scientific Advisory Board and Leadership Team to Advance Gene Therapy Development for Blindness Diseases - Nasdaq
Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team - GlobeNewswire
Ocugen Assembles Elite Gene Therapy Team: 3 Top Retina Experts Join as Company Targets Triple BLA Filing - Stock Titan
Ocugen doses first subject in trial of modifier gene therapy candidate - Yahoo Finance
Ocugen Bets Big On Gene Therapy Despite Major Setbacks - Finimize
Ocugen Doses First Patient in Pivotal Trial for Stargardt Gene Therapy - MyChesCo
Ocugen Announces Q2 2025 Financial Results Call and Business Update - MSN
Ocugen’s Phase 1 Study on OCU200: A Potential Game-Changer for Diabetic Macular Edema - TipRanks
Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 - GuruFocus
Ocugen doses first patient in phase 2/3 Stargardt disease trial - Investing.com Australia
Ocugen doses first patient in phase 2/3 Stargardt disease trial By Investing.com - Investing.com South Africa
Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 - GlobeNewswire
Revolutionary Gene Therapy Shows 48% Disease Slowdown in Stargardt Blindness Trial - Stock Titan
Ocugen Inc. Stock Analysis and ForecastUnbelievable profit margins - jammulinksnews.com
Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results - Ocugen
Ocugen to Host Conference Call on Friday, August 1 at 8:30 - GlobeNewswire
Ocugen Earnings: Gene Therapy Pioneer to Report Q2 2025 Results August 1 - Stock Titan
Stargardt Disease Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Nanoscope Therapeutics, Belite Bio, Biophytis, reVision Therapeutics, Inc - The Globe and Mail
Retina roundup: July 7 to July 11 - Modern Retina
Ouster Announces Date for Second Quarter 2025 Earnings Call - The Globe and Mail
Building Biotech Champions: Cultivating Breakthroughs In A Dynamic Field - Life Science Leader
OCGN ALERT– Nationally Ranked Shareholder Rights Firm Labaton Sucharow is Investigating Ocugen, Inc. (NASDAQ: OCGN) For Potential Securities Violations and Breach of Fiduciary Duty - ACCESS Newswire
Ocugen Receives Rare Pediatric Disease Designation for OCU410ST - MSN
Ocugen Granted Extension to Meet Nasdaq Listing Requirements - TipRanks
How did OCGN's Q4 earnings surprise impact its annual performance? - AInvest
After laying off most of its staff, struggling Carisma Therapeutics finds a merger partner - The Business Journals
Ocugen (OCGN) Receives Buy Rating Reiteration from HC Wainwright & Co. | OCGN Stock News - GuruFocus
Ocugen Soars 10.09% on OrthoCellix Merger News - AInvest
Carisma Therapeutics and OrthoCellix to Merge - citybiz
Ocugen’s IND amendment to begin phase 2/3 confirmatory trial of OCU410ST cleared by FDA - Modern Retina
Ocugen Receives FDA Clearance for Phase 2/3 Trial of Genetic Therapy for Stargardt Disease - MSN
Ocugen: Three Potential Gene-Therapy Filings By 2028 (NASDAQ:OCGN) - Seeking Alpha
FDA clears Ocugen’s IND amendment for trial of Stargardt disease treatment - Yahoo Finance
Finanzdaten der Ocugen Inc-Aktie (OCGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):